Results 151 to 160 of about 3,500 (185)

Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study. [PDF]

Inflamm Bowel Dis
Gisbert JP, Schreiber S, Siegel CA, Magro F, Jus A, Whichello C, Michaels-Igbokwe C, Heidenreich S, Oortwijn A, Vermeire S.   +9 more
europepmc   +1 more source

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis. [PDF]

Cureus
Burashed KK, AlAbbasi FA.
europepmc   +1 more source

[Overview of the new EULAR recommendations on antirheumatic therapy in reproduction, pregnancy and lactation]. [PDF]

Z Rheumatol
Meißner Y, Förger F.
europepmc   +1 more source

Adverse effects of Janus kinase inhibitors with relevance for daily practice in dermatology. [PDF]

J Dtsch Dermatol Ges
Rajput Khokhar A, Ghoreschi K, Huynh J.
europepmc   +1 more source

Clinical and Ultrasound Remission in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A Real-World Study. [PDF]

J Clin Med
Lasa-Teja C, Fernández-Cabero JJ, Sánchez-Bilbao L, Loricera J, González-Mazón I, Álvarez-Reguera C, Herrero-Morant A, Corrales-Martínez A, Portilla-González V, Martín-Varillas JL, Pérez-Garrido L, Santos-Gómez M, López-Hoyos M, Blanco R.   +13 more
europepmc   +1 more source

Second-line treatment strategies of ulcerative colitis after conventional therapy failure: A systematic review and network meta-analysis of randomized controlled trials. [PDF]

PLoS One
Xu Y, Jiang W, Jiang M, Zhu B, Huo J, Wu M, Yang L.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Filgotinib as rheumatoid arthritis therapy

Drugs of Today, 2021
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and progressive disability when inflammation cannot be sufficiently controlled. Despite treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs), up to 30% of RA patients do not reach or fail to ...
A, Becciolini, E, Di Donato, D, Santilli, G, Lucchini, F, Mozzani, M, Riva, A, Ariani   +6 more
openaire   +2 more sources

Filgotinib in rheumatoid arthritis

Expert Review of Clinical Immunology, 2022
Rheumatoid Arthritis (RA) remains a challenge for rheumatologists and patients despite implementation of intensive treat-to-target strategies in shared decision with patients and an increasing availability of drugs. Janus kinase inhibitors (JAKi) are a new generation of oral targeted drugs. Filgotinib preferentially inhibits JAK1 and is the latest JAKi
openaire   +2 more sources

Evaluating filgotinib for the treatment of rheumatoid arthritis

Expert Opinion on Pharmacotherapy, 2021
Despite the availability of an extensive armamentarium, rheumatoid arthritis (RA) remains a therapeutic challenge for rheumatologists. Janus kinase inhibitors (JAKi) are an emerging class of targeted therapies. The number of JAKi has been growing and to date, filgotinib is the latest JAKi to be approved for use in RA.This review focuses on the ...
Christophe Richez, Marie-Elise Truchetet
openaire   +2 more sources